Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 20/20 | 0.80 |
| ▸ | DRD2 | P14416 | 11/20 | 0.80 |
| ▸ | HTR2A | P28223 | 11/20 | 0.56 |
| ▸ | HTR2C | P28335 | 11/20 | 0.56 |
| ▸ | HTR2B | P41595 | 11/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7573331 | 0.95 | SIGMAR1 (0.73) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6836333 | 0.92 | SIGMAR1 (0.88) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6840820 | 0.90 | SIGMAR1 (0.93) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6840764 | 0.89 | SIGMAR1 (1.00) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6836351 | 0.85 | SIGMAR1 (0.69) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL9375055 | 0.81 | SIGMAR1 (1.00) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL9376355 | 0.80 | SIGMAR1 (1.00) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6841426 | 0.80 | SIGMAR1 (0.68) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL9374117 | 0.76 | SIGMAR1 (1.00) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6836353 | 0.75 | SIGMAR1 (0.62) | SIGMAR1DRD2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266802-A1 | Tricyclic analgesics | CALVET ALAIN (US) | 2004-12-30 | — | — | US | claimed |
| US-20040266802-A1 | Tricyclic analgesics | CALVET ALAIN (US) | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266802-A1 | Tricyclic analgesics | OPRM1, OPRL1, OPRD1 | SIGMAR1 11/4885DRD2 134/4885HTR2A 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.